AGM 2021

Jun 11, 2021

Good morning, and welcome to BioXcel Therapeutics, Inc. 2021 Annual Meeting of Stockholders. I would now like to introduce the 1st presenter, Chairman of the Board of Directors, Peter Mueller. Good morning, everybody. My name is Peter Mueller, the Chairman of the Board of Directors of BIAXA Therapeutics and the Chairperson of today's meeting. I'm very happy to welcome you to our 2021 Annual Meeting of Stockholders. On behalf of BioXcel Therapeutics, the members of the Board and company's management, I hope everyone is safe and healthy. Before I call the meeting to order, I'd like to introduce to you the other members of the Board of Directors who are with us today. The other members of the Board joining us today are Doctor. Vimal Mehta, our President and Chief Executive Officer Doctor. Krishnan Nandabalan June Pray, Doctor. Santeep Lomas and Doctor. Michal Vodrouva. In addition participating today are Richard Steinhardt, our Chief Financial Officer and Javier Rodriguez, our Chief Legal Officer. Also joining us is Devin Brady of Ernst and Young LLP, the company's independent registered public accounting firm, who is available to respond to relevant questions raised during the meeting. The meeting will now officially come to order. We will proceed with the formal business of the meeting as set forth in the notice of annual meeting and proxy statement. The time is 9:0:1 a. M. Eastern Time and the polls are open now for voting on all matters before the meeting. If you have not already voted and wish to vote, the polls will remain open until we finish presenting the proposals and close the polls. You do not need to vote during the meeting if you have already voted and do not wish to change your vote. Upon joining the meeting, an agenda for the meeting should have become available on your screen. Also available at the bottom of your screen is a list of the rules of conduct for this meeting. To conduct quarterly meeting, we may ask the participants abide by these rules. We will be responding to appropriate questions raised regarding the matters to be voted on at this meeting. If you would like to submit a question, you may enter question in the question and answers function on the Annual Meeting webpage. You must include your name and if applicable organization with your question. Each stockholder will be able to ask up to 2 questions. Note that only stockholders who are locked into the meeting using their 16 digit control number will be able to vote and submit questions at today's meetings. Our secretary will file the proof of mailing the notice of the meeting to stockholders of record on the record date with the company's records of the meeting. All stockholders of record at the close of business on April 12, 2021, or holders of a valid proxy are entitled to vote at the meeting. A complete list of the holders of record of the outstanding shares of the company's common stock on the record date for the meeting is available on your screen if you have logged into the meeting using your 16 digit control number. At this time, I'd like to introduce Angela Hartley, a representative of Broadridge Investor Communication Services. The Board of Directors has appointed a representative of Broadridge to act as Inspector of Election at today's meeting. Ms. Hartley has signed the customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. I have been informed that a quorum is present. Therefore, I hereby declare the meeting to be duly constituted for the transaction of business. We will now proceed with the formal business of this meeting. There are 4 proposals to be considered by the stockholders at today's meeting. The company recommends that the stockholders vote for each of the director nominees named in the first proposal and for the remaining three proposals. The first item of business is the election of Doctor. Dores Vimalmeda and Peter Mueller to serve as Class III directors of the company to hold office until the company's annual meeting of stockholders to be held in 2024. The second item of business is the ratification of the audit committee's appointment of Ernst and Young LLP as the company's independent registered public accounting firm for our 2021 fiscal year. The 3rd item of business is the approval of an amendment to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock of the company from $50,000,000 to $100,000,000 The 4th item of business is the approval of an adjournment of the annual meeting, if necessary, to solicit additional proxies there are not sufficient votes at the time of the annual meeting to approve proposal 3. That was the final proposal for today's meeting. As a reminder, for the purpose of today's meeting, we welcome only those questions from stockholders about the 4 proposals discussed. Please submit these via the question and answer text box on the Annual Meeting webpage. We will now take questions. Operator, are there any questions? There are no questions. All right. So with no questions, there are no more questions at this time. If you wish to vote and you haven't already, please vote now. If you wish to vote and you haven't already, please vote now by clicking on the voting button on the web portal and following the instructions. You do not need to vote electronically if you have already sent in your signed proxy or if you have voted by telephone or Internet unless you wish to change your vote. We will pause for approximately 30 seconds before closing the voting polls. So the time is now 9:0 Thank you very much. I have received the preliminary report of the Inspector of Election to be kept with the company's record of the Annual Meeting. Based on the preliminary report of the Inspector of Election, each of Doctor. Doris Vimal Alita and Peter Muir has been elected as a Director to serve until our annual meeting to be held in 2024. 2nd, the appointment of Ernst and Young LLP as our independent public accounting firm for our 2021 fiscal year has been ratified. 3rd, the amendment of the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock of the company from $50,000,000 to $100,000,000 has been approved. And finally, 4th, the adjournment of the annual meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the annual meeting to approve Proposal 3 has been approved. The final tally of the votes will be published within 4 business days in our current report on Form 8 ks to be filed with the Securities and Exchange Commission. It is now 9:0:9 a. M. Eastern Time and the formal portion of the meeting has concluded. With that, ladies and gentlemen, this completes our annual meeting and the meeting is now adjourned. I want to thank you for attending and for your continued support of BioXcel Therapeutics.